| Recent News & Press Releases can be found on the Home Page. September 25, 2007
Nephros Raises $12.7 Million in New Financing
Click here for additional information August 13, 2007
Nephros Reports Second Quarter 2007 Financial Results
Revenues Increase 15%, Net Loss is Reduced
Click here for additional information August 7, 2007
Nephros Discloses Nonpayment of Installment under the
Lancer Settlement Agreement in Current Report on Form 8-K
Click here for additional information July 20, 2007
Nephros Names New Independent Auditing Firm
Click here for additional information May 23, 2007
Nephros Reports Departure of Director
Click here for additional information May 16, 2007
Nephros to Initiate U.S. Clinical Trials
Click here for additional information May 15, 2007
Nephros Reports First Quarter 2007 Financial Results
Revenues Increase 70%, Net Loss is Reduced
Click here for additional information May 3, 2007
Nephros Provides Information Regarding Auditor's Going
Concern Report and Fiscal 2006 Results
Click here for additional information May 1, 2007
Nephros Reports Departure of Director
Click here for additional information March 1, 2007
Nephros Completes Informational Request from the FDA
on Investigational Device Exemption Application Nephros MD and H2H Technologies Clinical Trials Expected
to Commence in March 2007
Click here for additional information January 29, 2007
Nephros Receives Conditional Approval from the FDA of
Investigational Device Exemption Application Nephros MD and H2H Technologies Targeted to Begin Clinical
Trials in First Quarter 2007
Click here for additional information 2006 December 6, 2006
Italian Clinical Study Demonstrates Nephros’ Mid-Dilution HDF
Therapy As Optimal Treatment for Patients with Limited Vascular Access Dr. Renaux Presented Clinical Study Results at
American Society of Nephrology’s Renal Week 2006
Click here for additional information November 20, 2006
American Stock Exchange Will Continue Nephros’s Listing
Click here for additional information November 15, 2006
Nephros Reports Third Quarter 2006 Financial Results
Click here for additional information October 23, 2006
Multi-Center Study Concludes Nephros Mid-Dilution Hemodiafiltration
Therapy Achieves Higher Clearance of Low Molecular Weight Proteins
Study Abstract Selected by Peer-Review Experts for Presentation
at American Society of Nephrology (ASN) Congress
Click here for additional information October 5, 2006
Nephros Announces Positive Results of Clinical Study for Olpur™ MD190
Mid-Dilution Hemodiafiltration Filter
Study Findings to be Presented at October Nephrology Congress in Madrid.
Click here for additional information October 4, 2006
Nephros Selected for Development of Dual Stage Ultra Reliable Portable
Personal Water Filtration by U.S. Marine Corps ATD
$1 Million Department of Defense Appropriation Approved
Click here for additional information August 22, 2006
Nephros Announces Restatement of Financial Statements
Click here for additional information August 4, 2006
Nephros Selects Director William Fox to Serve as Executive Chairman.
Click here for additional information July 21, 2006
Nephros Receives Non-compliance Notification from AMEX.
Click here for additional information. May 24, 2006
Nephros to Present at Dutton Associates' ''Recognizing Opportunity''
Health Sciences SmallCap Conference in San Francisco May 31.
Click here to read the announcement.
Dutton Associates Small Cap Conference on Health Sciences 2006
http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=NEP&item_id=1325031 January 13, 2006
Nephros, Inc. (AMEX: NEP) announced today its first Purchase Order
from a major hospital in New York City for its new proprietary water
filtration device.
Click here for additional information. November 11, 2005
Nephros, Inc. (AMEX: NEP) announced today financial results for the
three months and nine months ended September 30, 2005.
Click here for additional information. October 26, 2005
Link to webcast of Nephros presentation at C.E. Unterberg Towbin Life Sciences
Conference http://www.wsw.com/webcast/ceut3/nephros October 19, 2005
Nephros, Inc. (AMEX: NEP) announced today it will present at the C.E.
Unterberg Towbin Emerging Growth Life Sciences Conference.
The Company is scheduled to present at 2:20 p.m. Eastern Time on
Wednesday, October 26th, at the Palace Hotel in New York City.
Click here for additional information. August 15, 2005
Nephros, Inc. (AMEX: NEP) announced today financial results for the three
months and six months ended June 30, 2005.
Click here for additional information. July 8, 2005
Nephros, Inc. (AMEX: NEP) announced today it has received confirmation
from the United States Patent and Trademark Office that it will be receiving
a patent on its OLpūr™ H2H™ product, which incorporates proprietary
technologies that allow users of conventional hemodialysis machines to
perform convective-based hemodiafiltration (HDF) therapies with on-line
ultra-pure substitution fluid.
Click here for additional information. June 17, 2005
Nephros, Inc. (AMEX: NEP), announced today that it received 510(k)
clearance for its OLpūr™ HD190 high flux filter from the United States
Food and Drug Administration (FDA). This 510(k) clearance allows Nephros
to market its OLpūr™ HD190 filter in the United States.
Click here for additional information. June 1, 2005
Nephros, Inc. (AMEX: NEP), announced today that it will be presenting
its line of proprietary renal products at two international renal conferences
in June 2005.
Click here for additional information. March 14, 2005
Nephros Announces 510(K) Filing with FDA for its OLpurT HD190
High Flux Filter.
Click here for additional information. March 2, 2005
Nephros Enters into Hemodiafilter Manufacturing and Distribution Rights
Agreement with Asahi Kasei Medical.
Click here for additional information. September 20, 2004
Nephros begins trading on the American Stock Exchange under the
ticker symbol NEP.
Click Here for additional information. June 4, 2004
Nephros first files with SEC for Public Offering.
Click here for additional information. | 
